uniQure Announces Results For First Quarter 2016

AMSTERDAM, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016, and provided a corporate update.

"We are very pleased with our progress so far in 2016 as we continue to advance our clinical and preclinical programs and build out our gene therapy platform," commented Daniel Soland, Chief Executive Officer of uniQure. "We achieved two important milestones related to our hemophilia B gene therapy AMT-060: announcing our first clinical data from the study's low-dose cohort and completing the dosing of all 10 patients in the study, including the high-dose cohort. Additionally, we presented and published data from several preclinical studies, including proof-of-concept data for AMT-130 in Huntington's disease and several new technologies designed to optimize gene therapy and expand its applicability to patients across the world. We look forward to presenting additional data on AMT-060 at EHA in June and remain on track to present new data from our high-dose cohort before the end of the year."

Back to news